

Amendment to Program Information

Bank of America Corporation

AMENDMENT TO PROGRAM INFORMATION

Type of Information:	Amendment to Program Information
Date of Announcement:	October 17, 2018
Issuer Name:	Bank of America Corporation
Name and Title of Representative:	John M. Pownall Managing Director
Address of Head Office:	Bank of America Corporate Center 100 N. Tryon Street Charlotte, North Carolina 28255 U.S.A.
Telephone:	+1 704 386 5681
Liaison Contact:	Attorney-in-Fact: Kazuhiro Yoshii, Attorney-at-law Yasunari Fuke, Attorney-at-law Kimiko Inoue, Attorney-at-law On Hagizawa, Attorney-at-law Asako Matsuo, Attorney-at-law Anderson Mori & Tomotsune Address: Otemachi Park Building 1-1, Otemachi 1-chome Chiyoda-ku, Tokyo Telephone: (03) 6775-1000
Type of Securities:	Notes
Address of Website for Announcement:	https://www.jpx.co.jp/equities/products/tpbm/announcement/index.html
Name of Arranger	Merrill Lynch International
Status of Submission of Annual Securities Reports or Issuer Filing Information:	Bank of America Corporation has continuously submitted Annual Securities Reports for more than one year. See such Annual Securities Reports and other reports filed by the Issuer in Japan which are available at the website http://disclosure.edinet-fsa.go.jp/ . See also reports filed by the Issuer with the U.S. Securities and Exchange Commission which are available at the website http://www.sec.gov/ .
Information on initial Program Information:	
Date of Announcement:	March 6, 2018
Scheduled Issuance Period:	March 7, 2018 to March 6, 2019
Maximum Outstanding Issuance Amount:	U.S.\$65,000,000,000

This amendment, consisting of this cover page and the Supplement dated October 16, 2018 to the Base Prospectus dated May 18, 2018 (and including, for the avoidance of doubt, the Offering Circular dated May 18, 2018 included therein), is filed to update the information included in the Program Information dated March 6, 2018 as amended by the amendments dated April 18, 2018, May 7, 2018, May 23, 2018, July 10, 2018, July 18, 2018 and August 1, 2018 (“Original Program Information”). This amendment shall be read together with the Original Program Information.



Bank of America Corporation
U.S. \$65,000,000,000
Euro Medium-Term Note Program

This supplement (the "**Supplement**"), which supplements the Base Prospectus dated May 18, 2018 (the "**Original Base Prospectus**") (as supplemented by the Supplementary Base Prospectus dated June 29, 2018, July 17, 2018 and July 31, 2018, the "**Base Prospectus**"), which together comprise a base prospectus for the purposes of Article 5.4 of the Directive 2003/71/EC (the "**Prospectus Directive**"), constitutes a supplementary prospectus for the purposes of section 87G of the Financial Services and Markets Act 2000 (the "**FSMA**") and is prepared in connection with the U.S. \$65,000,000,000 Euro Medium-Term Note Program (the "**Program**") of Bank of America Corporation (the "**Issuer**"). Terms defined in the Base Prospectus have the same meaning when used in this Supplement.

This Supplement is supplemental to, and shall be read in conjunction with, the Base Prospectus. To the extent that there is any inconsistency between any statement in this Supplement and any other statement in or incorporated by reference in the Base Prospectus, the statements in this Supplement will prevail.

The purpose of this Supplement is to: (i) incorporate by reference the Issuer's current report on Form 8-K dated October 15, 2018 (the "**October 15, 2018 Form 8-K**") in respect of the earnings press release relating to the nine months ended September 30, 2018; and (ii) update certain sections of the Base Prospectus as a result of a change in Singaporean law related product classification.

The Issuer accepts responsibility for the information contained in this Supplement. To the Issuer's best knowledge and belief (having taken all reasonable care to ensure that such is the case) the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Save as disclosed in this Supplement or in the document incorporated by reference in, and forming part of, this Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen or been noted, as the case may be, since the publication of the Base Prospectus as supplemented from time to time.

Incorporation by reference

The October 15, 2018 Form 8-K was filed with the United States Securities and Exchange Commission (the "**SEC**") on October 15, 2018 and with the Financial Conduct Authority. The October 15, 2018 Form 8-K shall be deemed to be incorporated by reference into, and form part of, this Supplement, other than the information under the headings "Item 7.01 Regulation FD Disclosure" (page 2*), "Exhibit 99.2" (entitled "The Presentation Materials") (pages 23* – 51*) and "Exhibit 99.3" (entitled "The Supplemental Information") (pages 52* – 92*) of the October 15, 2018 Form 8-K which shall not be deemed to be incorporated by reference into, or form part of, this Supplement. For the purposes of the prospectus rules made under section 73A of the FSMA and this Supplement, any information or other documents incorporated by reference, either expressly or implicitly, into the October 15, 2018 Form 8-K, or not deemed to have been filed as part of the October 15, 2018 Form 8-K under the rules of the SEC, do not form part of this Supplement. Information in the October 15, 2018 Form 8-K which is not incorporated by reference into the Base Prospectus is either not relevant for the investor or is covered elsewhere in the Base Prospectus.

* These page numbers are references to the PDF pages included in the October 15, 2018 Form 8-K.

Update to "Important Notice"

The section entitled "*Important Notice*" on page iii of the Base Prospectus shall be updated by including the following wording after the paragraph entitled "*Benchmark Regulations*":

"Notification under Section 309B(1) of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"): Unless otherwise stated in the Final Terms in respect of any Notes, all Notes issued or to be issued under the Program shall be prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in the Monetary Authority of Singapore (the "MAS") Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products)."

Update to Annex A – Form of Final Terms for Notes

On page 93 of the Base Prospectus, the section entitled "*Annex – Form of Final Terms for Notes*" shall be amended by including the following wording after the square bracketed paragraph entitled "*MIFID II product governance / Professional investors and eligible counterparties only target market*":

"[Notification under Section 309B(1) of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"): The Notes are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018 and Excluded Investment Products (as defined in the Monetary Authority of Singapore (the "MAS") Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products)]"

Update to "Offering Circular – Non-PD Notes"

The section entitled "Offering Circular – Non-PD Notes" on page 105 of the Offering Circular shall be updated by including the following wording after the paragraphs entitled "*MiFID II product governance / target market*":

"Notification under Section 309B(1) of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"): Unless otherwise stated in the Pricing Supplement in respect of any Non-PD Notes, all Non-PD Notes issued or to be issued under the Program shall be prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in the Monetary Authority of Singapore (the "MAS") Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products)."

Update to Form of Pricing Supplement

On page 147 of the Offering Circular, the section entitled "*Form of Pricing Supplement*" shall be amended by including the following wording after the square bracketed paragraph entitled "*MIFID II product governance / Professional investors and eligible counterparties only target market*":

"[Notification under Section 309B(1) of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"): The Notes are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018 and Excluded Investment Products (as defined in the Monetary Authority of Singapore (the "MAS") Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products)] "

Documents available for inspection

The Issuer will provide, without charge, to each person to whom a copy of this Supplement has been delivered, upon the oral or written request of such person, a copy of the document incorporated herein by reference. Written requests for such document should be directed to: Bank of America Corporation, Bank of America Corporate Center, 100 North Tryon Street, Charlotte, North Carolina 28255-0065, Attention: Fixed Income Investor Relations or fixedincomeir@bankofamerica.com. Telephone requests may be directed to +1-866-607-1234 (toll free) or +1-212-449-6795. The Issuer's filings with the SEC are available through (1) the SEC's website at www.sec.gov, or the SEC's Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549, and (2) the Issuer's website at <http://investor.bankofamerica.com/phoenix.zhtml?c=71595&p=irol-sec#fbid=vPBmqoqUe99>. References to web addresses in this Supplement are included as inactive textual references only. Except as specifically incorporated by reference in this Supplement, information on these websites is not part of this Supplement.